Cataract progression · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher cataract progression ‐ 36 months compared with sham (moderate certainty).
1 finding from 1 review
Use of IOP‐lowering medications · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher use of IOP‐lowering medications ‐ 36 months compared with sham (moderate certainty).
1 finding from 1 review
Surgery for glaucoma · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg showed no clear difference in surgery for glaucoma ‐ 36 months compared with sham (low certainty).
1 finding from 1 review
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · macular edema in diabetes
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Gain 3+ lines of visual acuity at 1 year · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg may leads to lower gain of three or more lines visual acuity ‐ 12 months compared with intravitreal antiVEGF (low certainty).
1 finding from 1 review
RR 0.99
Studies not reported
Low
Change in retinal thickness (micron) ‐ 12 months (negative is better) · macular edema in diabetes
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · macular edema in diabetes
1 finding from 1 review
Gain 3+ lines of visual acuity at 1 year · macular edema in diabetes
Intravitreal fluocinolone acetonide implant 0.19 mg probably leads to higher gain of three or more lines visual acuity ‐ 12 months compared with sham (moderate certainty).
1 finding from 1 review
Change in retinal thickness (micron) ‐ 12 months (negative is better) · macular edema in diabetes
1 finding from 1 review
Cataract progression ‐ 24 months · macular edema in diabetes
Intravitreal fluocinolone acetonide implant 0.19 mg probably leads to higher cataract progression ‐ 24 months compared with sham (moderate certainty).
1 finding from 1 review
Use of IOP‐lowering medications ‐ 24 months · macular edema in diabetes
Intravitreal fluocinolone acetonide implant 0.19 mg probably leads to higher use of IOP‐lowering medications ‐ 24 months compared with sham (moderate certainty).
1 finding from 1 review
Surgery for glaucoma ‐ 24 months · macular edema in diabetes
Intravitreal fluocinolone acetonide implant 0.19 mg may leads to higher surgery for glaucoma ‐ 24 months compared with sham (low certainty).
1 finding from 1 review